The Triple-Combination Therapy of TG-1101, TGR-1202, and ibrutinib to be Highlighted in an Oral Presentation
Updates on the Combination of TG-1101 Plus TGR-1202, and Single-Agent TGR-1202 to be Featured in Poster Presentations
NEW YORK, May 13, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that updated data for TG-1101 (ublituximab), the Company's novel, glycoengineered anti-CD20 monoclonal antibody, and TGR-1202, the Company's PI3K delta inhibitor, has been selected for presentation at the upcoming 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from May 29 – June 2, 2015, at McCormick Place in Chicago, Illinois.
The presentation schedule at ASCO 2015 is as follows:
Oral Presentation:
-
Title: Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies
- Abstract Number: 8501
- Presentation Date & Time: Monday, June 1, 2015, 9:57AM – 10:09AM CT
- Session Type/Track: Oral Abstract Session/ Lymphoma and Plasma Cell Disorders
- Presenter: Nathan H. Fowler, MD, University of Texas MD Anderson Cancer Center
Poster Presentations:
-
Title: Ublituximab plus TGR-1202 activity and safety profile in relapsed/refractory B-cell NHL and high-risk CLL
- Abstract Number: 8548
- Presentation Date & Time: Sunday, May 31, 2015, 8:00AM – 11:30AM CT
- Track: Lymphoma and Plasma Cell Disorders
-
Presenter: Matthew A. Lunning, DO, University of Nebraska Medical Center
-
Title: Clinical activity and safety profile of TGR-1202, a novel once daily PI3K delta inhibitor, in patients with CLL and B-cell lymphoma
- Abstract Number: 7069
- Presentation Date & Time: Sunday, May 31, 2015, 8:00AM – 11:30AM CT
- Track: Leukemia, Myelodysplasia, and Transplantation
- Presenter: Howard A. Burris, MD, Sarah Cannon Research Institute, Tennessee Oncology, PLLC
A copy of the ASCO abstracts were made available today, May 13, 2015 at 5:00pm ET through the ASCO meeting website at www.asco.org. Following each presentation, the date presented will be available on the Publications page, located within the Pipeline section, of the Company's website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs to develop IRAK4 inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
Cautionary Statement
Some of the statements included in this press release, particularly those with respect to anticipating future clinical trials, the timing of commencing or completing such trials and business prospects for TG-1101, TGR-1202, the IRAK4 inhibitor program, and the anti-PD-L1 and anti-GITR antibodies may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR antibodies; the risk that early pre-clinical and clinical results that supported our decision to move forward with TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR antibodies will not be reproduced in additional patients or in future studies; the risk that trends observed which underlie certain assumptions of future performance of TGR-1202 will not continue, the risk that TGR-1202 will not produce satisfactory safety and efficacy results to warrant further development following the completion of the current Phase 1 study; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
TGTX - G